In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
GBG Jahrestreffen vom 24. bis 26. Februar 2021 wissenschaftliche Veranstaltung
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
A new consortium of the EU Innovative Medicines Initiative (IMI) will establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
Entscheidungshilfen zur Durchführung einer COVID-19-Impfung bei Studienpatienten.
Save the date: Virtuelles State of the Art Meeting am 27. Februar.
A translational research project evaluating effect of chemotherapy on different immune subsets in TNBC patients from GeparNuevo trial was published in Journal for ImmunoTherapy of Cancer
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
We are delighted to inform you that results from GeparOLA trial have been published in Annals of Oncology.
Erste Patientin eingebracht.
NSABP und GBG freuen sich bekannt zu geben, dass der 1000. Patient für die GeparDouze-Studie randomisiert wurde.
Analysis of breast cancer patients with asymptomatic brain metastases from BMBC registry has been published in Cancers (Basel).
A translational research project evaluating the MGMT promoter methylation status in TNBC from GeparSixto has been published in PLoSOne
Kampagne „ICH BIN DABEI! Brustkrebs verstehen – wir unterstützen die Veranstaltung!
PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive, human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed.
Data of several GBG studies was presented at the upcoming ESMO Virtual Meeting 2020, which took place from 19 to 21 September 2020.
Große internationale Multicenter-Studie (TAXIS) vergleicht zwei chirurgische Therapiekonzepte bei Brustkrebs mit Lymphknotenbefall / Prof. Dr. Jörg Heil
A research project investigating tumor mutational burden and immune gene expression profile for response to neoadjuvant treatment in early TNBC has been published in Annals of Oncology
We are delighted to inform you that results from a quality assurance process integrated into the INSEMA trial have been published in International Journal of Radiation Oncology, Biology, Physics.
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence